Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 7 (July)

1. Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
   Int J Clin Oncol, 10(3): 204-7. [Abstract] [Full-text]
2. Substance-P-mediated immunomodulation of tumor growth in a murine model.
   Neuroimmunomodulation, 12(4): 201-10. [Abstract] [Full-text]
3. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
   Cancer Biother Radiopharm, 20(3): 280-9. [Abstract] [Full-text]
4. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
   Nat Genet, 37(7): 745-9. [Abstract] [Full-text]
5. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
   Cancer Res, 65(13): 5857-63. [Abstract] [Full-text]
6. Interaction between integrin alpha(5) and fibronectin is required for metastasis of B16F10 melanoma cells.
   Biochem Biophys Res Commun, 333(4): 1269-75. [Abstract] [Full-text]
7. Predictors of self-reported confidence ratings for adult recall of early life sun exposure.
   Am J Epidemiol, 162(2): 183-92. [Abstract] [Full-text]
8. Primary choroidal melanoma in phakomatosis pigmentovascularis IIa.
   Ophthalmology, 112(7): 1232-5. [Abstract] [Full-text]
9. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
   J Natl Cancer Inst, 97(13): 998-1007. [Abstract] [Full-text]
10. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.
    J Exp Med, 202(1): 61-72. [Abstract] [Full-text]
11. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells.
    J Cell Biol, 170(1): 49-59. [Abstract] [Full-text]
12. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
    Cancer Immunol Immunother, 54(9): 891-7. [Abstract] [Full-text]
13. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.
    Cancer Immunol Immunother, 54(9): 907-14. [Abstract] [Full-text]
14. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
    Cancer Immunol Immunother, 54(9): 815-25. [Abstract] [Full-text]
15. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
    Nature, 436(7047): 117-22. [Abstract] [Full-text]
16. Interaction of human Thy-1 (CD 90) with the integrin alphavbeta3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium.
    Oncogene, 24(29): 4710-20. [Abstract] [Full-text]
17. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels.
    J Clin Invest, 115(7): 1816-27. [Abstract] [Full-text]
18. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.
    J Clin Invest, 115(7): 1903-12. [Abstract] [Full-text]
19. The chemoresistance gene ABCG2 (MXR/BCRP1/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin.
    J Cutan Pathol, 32(7): 467-73. [Abstract] [Full-text]
20. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
    Genes Chromosomes Cancer, 44(1): 10-8. [Abstract] [Full-text]
21. Immuno-gene therapy of melanoma by tumor antigen epitope modified IFN-gamma.
    Cancer Immunol Immunother, 54(8): 741-9. [Abstract] [Full-text]
22. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
    Hum Pathol, 36(6): 676-85. [Abstract] [Full-text]
23. Dose and time dependent apoptotic response in a human melanoma cell line exposed to accelerated boron ions at four different LET.
    Int J Radiat Biol, 81(4): 261-72. [Abstract] [Full-text]
24. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53.
    Biochem Biophys Res Commun, 334(1): 223-30. [Abstract] [Full-text]
25. "Finger-tip" cryotherapy probes: treatment of squamous and melanocytic conjunctival neoplasia.
    Br J Ophthalmol, 89(8): 942-5. [Abstract] [Full-text]
26. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Cancer Res, 65(14): 6425-34. [Abstract] [Full-text]
27. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Cancer Res, 65(14): 6294-304. [Abstract] [Full-text]
28. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Cancer Res, 65(14): 6282-93. [Abstract] [Full-text]
29. The role of sentinel lymph node biopsy in the management of thin melanoma.
    Am J Surg, 190(2): 196-9. [Abstract] [Full-text]
30. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles.
    Int J Cancer, 116(4): 624-33. [Abstract] [Full-text]
31. Adrenal metastases of malignant melanoma: characteristic computed tomography appearances.
    Australas Radiol, 49(4): 325-9. [Abstract] [Full-text]
32. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience.
    Int J Radiat Oncol Biol Phys, 62(5): 1405-11. [Abstract] [Full-text]
33. Combined effects of GSTP1 and MRP1 in melanoma drug resistance.
    Br J Cancer, 93(2): 216-23. [Abstract] [Full-text]
34. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma.
    J Clin Oncol, 23(21): 4764-70. [Abstract] [Full-text]
35. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.
    J Clin Oncol, 23(21): 4735-41. [Abstract] [Full-text]
36. Uveal and conjunctival malignant melanoma in Denmark, 1943-97: incidence and validation study.
    Ophthalmic Epidemiol, 12(4): 223-32. [Abstract] [Full-text]
37. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
    Immunol Cell Biol, 83(4): 344-51. [Abstract] [Full-text]
38. Fatty acid synthase expression in cutaneous melanocytic neoplasms.
    Mod Pathol, 18(8): 1107-12. [Abstract] [Full-text]
39. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery.
    J Surg Oncol, 91(2): 120-5. [Abstract] [Full-text]
40. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    J Surg Oncol, 91(2): 107-11. [Abstract] [Full-text]
41. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Cancer, 104(3): 570-9. [Abstract] [Full-text]
42. Microvessel density for melanoma prognosis.
    Histopathology, 47(2): 186-94. [Abstract] [Full-text]
43. Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed Sargassum stenophyllum.
    Cancer Chemother Pharmacol, 56(4): 436-46. [Abstract] [Full-text]
44. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    NMR Biomed, 18(5): 308-21. [Abstract] [Full-text]
45. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
    J Clin Oncol, 23(22): 5088-93. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.